当前位置: X-MOL 学术Biomarkers › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Renalase in children with chronic kidney disease.
Biomarkers ( IF 2.6 ) Pub Date : 2019-07-23 , DOI: 10.1080/1354750x.2019.1642957
Piotr Skrzypczyk 1 , Magdalena Okarska-Napierała 1, 2 , Anna Stelmaszczyk-Emmel 3 , Elżbieta Górska 3 , Małgorzata Pańczyk-Tomaszewska 1
Affiliation  

Background: Renalase is kidney-derived molecule initially considered as catecholamine-inactivating enzyme. However, recent studies suggest that renalase exerts potent cardio- and nephroprotective actions, not related to its enzymatic activity. Purpose: To assess renalase level in children with chronic kidney disease (CKD). Material and methods: Serum renalase, BMI, arterial stiffness, peripheral and central blood pressure, intima-media thickness (IMT), medications, and biochemical parameters were analyzed in 38 children with CKD (12.23 ± 4.19 years) (stage G2-5). Control group consisted of 38 healthy children. Results: In the study group, GFR was 25.74 ± 8.94 mL/min/1.73 m2; 6 children were dialyzed; 26 had arterial hypertension. Renalase level was higher in the study group compared to control group (p < 0.001). In CKD children renalase correlated (p < 0.05) with BMI Z-score (r = -0.36), alfacalcidol dose (r = 0.41), GFR (r = -0.69), hemoglobin (r = -0.48), total cholesterol (r = 0.35), LDL-cholesterol (r = 0.36), triglycerides (r = 0.52), phosphate (r = 0.35), calcium-phosphorus product (r = 0.35), parathormone (r = 0.58), and pulse wave velocity Z-score (r = 0.42). In multivariate analysis GFR (β = -0.63, p < 0.001), triglycerides (β = 0.59, p = 0.002), and alfacalcidol dose (β = -0.49, p = 0.010) were determinants of renalase. Conclusions: In children with CKD there is a strong correlation between renalase level and CKD stage. Furthermore, in these patients renalase does not correlate with blood pressure but may be a marker of arterial stiffness.

中文翻译:

慢性肾脏病患儿的肾病酶。

背景:肾病酶是最初源自儿茶酚胺失活酶的肾脏衍生分子。但是,最近的研究表明,肾酶具有强力的心脏和肾脏保护作用,与其酶活性无关。目的:评估慢性肾脏病(CKD)患儿的肾脏酶水平。材料和方法:分析了38例CKD儿童(12.23±4.19岁)(G2-5期)的血清肾酶,BMI,动脉僵硬度,外周和中心血压,内膜中层厚度(IMT),药物和生化参数。 。对照组由38名健康儿童组成。结果:研究组的GFR为25.74±8.94mL / min / 1.73m2。透析了6个孩子;26岁患有动脉高血压。与对照组相比,研究组的肾酶水平更高(p <0.001)。在CKD儿童中,肾酶与BMI Z评分(r = -0.36),阿法骨化醇剂量(r = 0.41),GFR(r = -0.69),血红蛋白(r = -0.48),总胆固醇(r)相关(p <0.05) = 0.35),LDL-胆固醇(r = 0.36),甘油三酸酯(r = 0.52),磷酸盐(r = 0.35),钙磷产物(r = 0.35),副甲状腺激素(r = 0.58)和脉搏波速度Z-得分(r = 0.42)。在多变量分析中,GFR(β= -0.63,p <0.001),甘油三酸酯(β= 0.59,p = 0.002)和阿法骨化醇剂量(β= -0.49,p = 0.010)是肾酶的决定因素。结论:CKD患儿的肾脏酶水平与CKD分期密切相关。此外,在这些患者中,肾酶与血压无关,但可能是动脉僵硬的标志。血红蛋白(r = -0.48),总胆固醇(r = 0.35),LDL-胆固醇(r = 0.36),甘油三酸酯(r = 0.52),磷酸盐(r = 0.35),钙磷产品(r = 0.35),副胸腺激素(r = 0.58)和脉搏波速度Z分数(r = 0.42)。在多变量分析中,GFR(β= -0.63,p <0.001),甘油三酸酯(β= 0.59,p = 0.002)和阿法骨化醇剂量(β= -0.49,p = 0.010)是肾酶的决定因素。结论:CKD患儿的肾脏酶水平与CKD分期密切相关。此外,在这些患者中,肾酶与血压无关,但可能是动脉僵硬的标志。血红蛋白(r = -0.48),总胆固醇(r = 0.35),LDL-胆固醇(r = 0.36),甘油三酸酯(r = 0.52),磷酸盐(r = 0.35),钙磷产品(r = 0.35),副胸腺激素(r = 0.58)和脉搏波速度Z分数(r = 0.42)。在多变量分析中,GFR(β= -0.63,p <0.001),甘油三酸酯(β= 0.59,p = 0.002)和阿法骨化醇剂量(β= -0.49,p = 0.010)是肾酶的决定因素。结论:CKD患儿的肾脏酶水平与CKD分期密切相关。此外,在这些患者中,肾酶与血压无关,但可能是动脉僵硬的标志。在多变量分析中,GFR(β= -0.63,p <0.001),甘油三酸酯(β= 0.59,p = 0.002)和阿法骨化醇剂量(β= -0.49,p = 0.010)是肾酶的决定因素。结论:CKD患儿的肾脏酶水平与CKD分期密切相关。此外,在这些患者中,肾酶与血压无关,但可能是动脉僵硬的标志。在多变量分析中,GFR(β= -0.63,p <0.001),甘油三酸酯(β= 0.59,p = 0.002)和阿法骨化醇剂量(β= -0.49,p = 0.010)是肾酶的决定因素。结论:CKD患儿的肾脏酶水平与CKD分期密切相关。此外,在这些患者中,肾酶与血压无关,但可能是动脉僵硬的标志。
更新日期:2019-07-23
down
wechat
bug